Fineline Cube

Follow:
14855 Articles
Jiangsu Vcare's VC005 JAK1 Inhibitor Wins CDE IND Approval for Seborrheic Dermatitis – Fourth Topical Indication for Next‑Generation Molecule
CompanyDrug

Jiangsu Vcare’s VC005 JAK1 Inhibitor Wins CDE IND Approval for Seborrheic Dermatitis – Fourth Topical Indication for Next‑Generation Molecule

GSK Q3 2026 Revenue Rises 5% to GBP 8.9 Billion as Specialty Medicines Surge 15%, Vaccines Stumble on Weak Shingrix China Demand
Company

GSK Q3 2026 Revenue Rises 5% to GBP 8.9 Billion as Specialty Medicines Surge 15%, Vaccines Stumble on Weak Shingrix China Demand

Hengrui Pharma Q3 2026 Revenue Jumps 20.55% and Non-Recurring Net Profit Nearly Doubles – Innovative Drugs Now Drive 65% of Drug Sales as Generics Shrink
Company

Hengrui Pharma Q3 2026 Revenue Jumps 20.55% and Non-Recurring Net Profit Nearly Doubles – Innovative Drugs Now Drive 65% of Drug Sales as Generics Shrink

Kelun Pharma's Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD's KEYTRUDA
CompanyDrug

Kelun Pharma’s Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD’s KEYTRUDA

Fosun Pharma Posts 9M 2026 Results – Revenue Rises 5.81% to RMB 30.5 Billion as Innovative Drug Growth Fuels Profits and R&D Spending Surges 31%
Company

Fosun Pharma Posts 9M 2026 Results – Revenue Rises 5.81% to RMB 30.5 Billion as Innovative Drug Growth Fuels Profits and R&D Spending Surges 31%

Joincare's LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty
CompanyDrug

Joincare’s LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty

Hengrui's Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care
CompanyDrug

Hengrui’s Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care

Enhertu Wins EU Approval in Resected HER2-Positive Breast Cancer – Daiichi Sankyo's ADC Cuts Recurrence Risk by 53% Versus T-DM1
CompanyDrug

Enhertu Wins EU Approval in Resected HER2-Positive Breast Cancer – Daiichi Sankyo’s ADC Cuts Recurrence Risk by 53% Versus T-DM1

Astellas Inks Exclusive Option and License Deal for Audax's DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy
CompanyDeals

Astellas Inks Exclusive Option and License Deal for Audax’s DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Livzon Pharma's LZSN2501 Wins NMPA Clinical Trial Approval for VTE Prevention After Knee Arthroplasty – Bi-Epitopic Bispecific Anti-FXI Antibody Targets Next-Generation Anticoagulation
CompanyDrug

Livzon Pharma’s LZSN2501 Wins NMPA Clinical Trial Approval for VTE Prevention After Knee Arthroplasty – Bi-Epitopic Bispecific Anti-FXI Antibody Targets Next-Generation Anticoagulation

GeneScience's GenSci136 Wins NMPA Clinical Trial Approval for Sjögren's Syndrome – Proprietary Dual-Target BAFF/APRIL Antagonist Advances Changchun High-Tech's Autoimmune Pipeline
CompanyDrug

GeneScience’s GenSci136 Wins NMPA Clinical Trial Approval for Sjögren’s Syndrome – Proprietary Dual-Target BAFF/APRIL Antagonist Advances Changchun High-Tech’s Autoimmune Pipeline

China's National Joint Procurement Office Disqualifies Eugia Pharma and JSC "Farmak" Over Supply Failures – Four‑Year and Two‑Year Bans Imposed Under Centralized Drug Procurement Rules
Policy / Regulatory

China’s National Joint Procurement Office Disqualifies Eugia Pharma and JSC “Farmak” Over Supply Failures – Four‑Year and Two‑Year Bans Imposed Under Centralized Drug Procurement Rules